Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding Wages, Salaries and Other

Ratios

Lexeo Therapeutics (LXEO) Shares Issued (2022 - 2026)

Lexeo Therapeutics' Shares Issued history spans 2 years, with the latest figure at $100.2 million for Q4 2023.

On a quarterly basis, Shares Issued rose 357757.14% to $100.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $100.3 million, a N/A change, with the full-year FY2025 number at $59000.0, down 99.94% from a year prior.
Shares Issued hit $100.2 million in Q4 2023 for Lexeo Therapeutics, up from $30000.0 in the prior quarter.
Over the last five years, Shares Issued for LXEO hit a ceiling of $100.2 million in Q4 2023 and a floor of $9000.0 in Q2 2023.